When a tumor is surgically removed, small amounts of residual cancer can remain at a level that is undetectable with current imaging or blood-based approaches. In this interview, Technology Networks spoke with Asaf Zviran, co-founder and CEO of C2i Genomics to find out more about the company’s C2-Intelligence Platform for the detection of trace amounts of cancer.Read More
A new body of work published in Science Translational Medicine outlines the preclinical testing of a microRNA-based gene therapy for Huntington's disease – AMT-130 – in minipigs.Read More
In this interview, Technology Networks spoke with Neal Goodwin, PhD, Chief Scientific Officer at Teknova, to learn more about current bioprocessing and bioproduction trends in the cell and gene therapy space. Goodwin also discusses the impact of the COVID-19 pandemic on the biopharmaceutical sector and highlights how the industry has united to contribute to the development of vaccines at this critical time.Read More
Progenity’s Christopher Wahl provides his insights into the research and work being done specifically with Progenity’s novel ingestible lab-in-a-capsule, PIL Dx.Read More
As COVID-19 vaccination programs kick into gear, private and public workplaces are weighing up the risks and benefits of asking employees to return to the office. Affinity Empowering Inc, who offer workplace eHealth compliance services, have rolled out an end-to-end COVID-19 testing program to assist employers in their return to work protocols. We spoke to Affinity CEO Scott Storrer to find out more.
While S-ketamine has now become licensed as the antidepressant nasal spray Spravato, research into its mirror molecule has been more limited. Now, drug developers say that R-ketamine could potentially deliver a more targeted action with fewer side effects than its more popular twin.Read More
Technology Networks had the pleasure of speaking with Ki-Sung Kwon, head of the R&D unit at Celltrion to learn more about therapeutic versus preventive strategies against COVID-19 and the company's monoclonal antibody-based therapeutic – CT-P59 – that is currently being developed against COVID-19.Read More
Animal-free testing methods are being increasingly explored and implemented as an alternative to animal models, in efforts to provide a more accurate prediction of a drug candidate’s efficacy and safety. InSphero recently hosted a virtual roundtable discussion on the topic of animal-free testing. Technology Networks had the pleasure of speaking with Armin Wolf, chief scientific officer at InSphero, to learn more about the topics discussed.Read More